Table 1.
Overview of results from meta-analyses on oesophageal adenocarcinoma (OAC) risk in patients with Barrett’s oesophagus (BO).
| Reference | Studies (n) | OAC Incidence rate* (95% CI) |
HGD/OAC Incidence rate (95% CI) |
|---|---|---|---|
| Shaheen et al. (2000) | 25 | 5.0 (x-x) | -- |
| Chang et al. (2007) | 14 | 6.3 (3.6–10.1) | -- |
| Thomas et al. (2007) | 41 | 7 (6–9) | 9 (5–16) |
| Yousef et al. (2008) | 47 | 4.1 (3.1–5.5) | 9.3 (6.3–14) |
|
Wani et al. (2009) NDBO LGD |
45 16 |
6,0 (5.1–6.9) 17 (13–21) |
-- -- |
| Sikkema et al. (2010) | 50 | 6.3 (4.7–8.4) | 10.2 (7.5–14) |
|
Desai et al. (2012) NDBO |
57 |
3.3 (2.8–3.8) |
-- |
*
Incidence rate per 1000 person years
**
NDBO: non dysplastic Barrett’s oesophagus; LGD: low-grade dysplasia; HGD: high grade dysplasia; OAC: oesophageal adenocarcinoma; CI: confidence interval